PBS rules flouted for diabetes drugs

Sulfonylureas are being shunned in favour of newer, expensive drugs for type 2 diabetes that are widely prescribed outside of PBS criteria, a review by the PBAC finds.

About 30% of all prescribing of third-line agents for type 2 diabetes was beyond PBS restrictions, according to a draft report.

Released earlier this month, the PBAC report found that newer drugs had contributed to a blowout in PBS expenditure on type 2 diabetes medicines, with costs